Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.

Zhang R, Wu X, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2011 Dec 1;19(23):7023-32. doi: 10.1016/j.bmc.2011.10.012. Epub 2011 Oct 14.

2.

The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

Hasinoff BB, Liang H, Wu X, Guziec LJ, Guziec FS Jr, Marshall K, Yalowich JC.

Bioorg Med Chem. 2008 Apr 1;16(7):3959-68. doi: 10.1016/j.bmc.2008.01.033. Epub 2008 Jan 26.

3.

The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.

Hasinoff BB, Zhang R, Wu X, Guziec LJ, Guziec FS Jr, Marshall K, Yalowich JC.

Bioorg Med Chem. 2009 Jul 1;17(13):4575-82. doi: 10.1016/j.bmc.2009.04.072. Epub 2009 May 6.

PMID:
19457675
4.

Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.

Zhang R, Wu X, Guziec LJ, Guziec FS, Chee GL, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. doi: 10.1016/j.bmc.2010.04.028. Epub 2010 Apr 18.

5.

N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.

Baviskar AT, Madaan C, Preet R, Mohapatra P, Jain V, Agarwal A, Guchhait SK, Kundu CN, Banerjee UC, Bharatam PV.

J Med Chem. 2011 Jul 28;54(14):5013-30. doi: 10.1021/jm200235u. Epub 2011 Jun 23.

PMID:
21644529
6.
7.

A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.

Liang H, Wu X, Guziec LJ, Guziec FS Jr, Larson KK, Lang J, Yalowich JC, Hasinoff BB.

J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35.

PMID:
16859314
8.

Synthesis and cytotoxic activity of a new potential DNA bisintercalator: 1,4-Bis{3-[N-(4-chlorobenzo[g]phthalazin-1-yl)aminopropyl]}piperazine.

Galisteo J, Navarro P, Campayo L, Yunta MJ, Gómez-Contreras F, Villa-Pulgarin JA, Sierra BG, Mollinedo F, Gonzalez J, Garcia-España E.

Bioorg Med Chem. 2010 Jul 15;18(14):5301-9. doi: 10.1016/j.bmc.2010.05.053. Epub 2010 May 24.

PMID:
20538470
9.

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.

Cancer Res. 1998 Apr 1;58(7):1460-8.

10.

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.

Yalowich JC, Wu X, Zhang R, Kanagasabai R, Hornbaker M, Hasinoff BB.

Biochem Pharmacol. 2012 Jul 1;84(1):52-8. doi: 10.1016/j.bcp.2012.03.021. Epub 2012 Apr 4.

11.

A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.

Liang H, Wu X, Yalowich JC, Hasinoff BB.

Mol Pharmacol. 2008 Mar;73(3):686-96. Epub 2007 Nov 28.

12.

Synthesis, biological evaluation and modeling studies of terphenyl topoisomerase IIα inhibitors as anticancer agents.

Qiu J, Zhao B, Zhong W, Shen Y, Lin H.

Eur J Med Chem. 2015 Apr 13;94:427-35. doi: 10.1016/j.ejmech.2015.03.010. Epub 2015 Mar 6.

PMID:
25800514
13.

Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.

Bau JT, Kurz EU.

Biochem Pharmacol. 2014 Jun 15;89(4):464-76. doi: 10.1016/j.bcp.2014.03.011. Epub 2014 Mar 30.

PMID:
24695359
14.

Structure-activity studies with cytotoxic anthrapyrazoles.

Begleiter A, Lin D, Larson KK, Lang J, Wu X, Cabral T, Taylor H, Guziec LJ, Kerr PD, Hasinoff BB, Guziec FS Jr.

Oncol Rep. 2006 Jun;15(6):1575-80.

PMID:
16685398
15.

Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.

Wakelin LP, Bu X, Eleftheriou A, Parmar A, Hayek C, Stewart BW.

J Med Chem. 2003 Dec 18;46(26):5790-802.

PMID:
14667232
16.

Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα.

Pogorelčnik B, Brvar M, Žegura B, Filipič M, Solmajer T, Perdih A.

ChemMedChem. 2015 Feb;10(2):345-59. doi: 10.1002/cmdc.201402459. Epub 2014 Dec 17.

PMID:
25522133
17.

Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.

Jun KY, Lee EY, Jung MJ, Lee OH, Lee ES, Park Choo HY, Na Y, Kwon Y.

Eur J Med Chem. 2011 Jun;46(6):1964-71. doi: 10.1016/j.ejmech.2011.01.011. Epub 2011 Jan 15.

PMID:
21419530
18.

3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.

Park SE, Chang IH, Jun KY, Lee E, Lee ES, Na Y, Kwon Y.

Eur J Med Chem. 2013 Nov;69:139-45. doi: 10.1016/j.ejmech.2013.07.048. Epub 2013 Aug 11.

PMID:
24013413
19.

Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.

Kamal A, Suresh P, Ramaiah MJ, Mallareddy A, Imthiajali S, Pushpavalli SN, Lavanya A, Pal-Bhadra M.

Bioorg Med Chem. 2012 Mar 15;20(6):2054-66. doi: 10.1016/j.bmc.2012.01.039. Epub 2012 Feb 9.

PMID:
22364746
20.

Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.

Pogorelčnik B, Perdih A, Solmajer T.

Curr Med Chem. 2013;20(5):694-709. Review.

PMID:
23210851
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk